Vitamin D and Calcium Addition during Denosumab Therapy over a Period of Four Years Significantly Improves Lumbar Bone Mineral Density in Japanese Osteoporosis Patients.
Vitamin D and Calcium Addition during Denosumab Therapy over a Period of Four Years Significantly Improves Lumbar Bone Mineral Density in Japanese Osteoporosis Patients.
复制标题
DOI：
10.3390/nu10030272
复制
发表时间：
2018-02-27
期刊：
影响因子：
5.9
通讯作者：
Kato H
中科院分区：
文献类型：
--
作者：
Suzuki T;Nakamura Y;Kato H
本研究调查了在原发性骨质疏松症患者中，在为期4年的Denosumab治疗期间，维生素D和钙补充剂是否影响骨代谢和骨矿物质密度（BMD）。将患者分为地舒单抗单药治疗组（22例）或地舒单抗加维生素D和钙补充剂组（联合治疗组，21例）。在基线和治疗12、24、36和48个月时，我们测量了血清骨碱性磷酸酶（BAP）、抗酒石酸酸性磷酸酶（TRACP）-5b、尿I型胶原N末端肽（NTX）、腰椎1-4椎体（L-BMD）和双侧髋部（H-BMD）的BMD。患者背景无显著差异。与基线值相比，两组在12至48个月期间的血清BAP、TRACP-5 b和尿NTX均受到显著抑制。L-BMD在两组的每个时间点均显著增加，而H-BMD仅在联合组的每个时间点均显著增加。两组在24、36、48个月时L-BMD和12个月时H-BMD差异均有统计学意义（P <0.05）。与地舒单抗单药治疗相比，地舒单抗+维生素D和钙联合治疗在12个月时显著增加了H-BMD，在24至48个月时显著增加了L-BMD。这些结果表明，持续补充维生素D和钙是重要的，特别是12个月，以改善H-BMD和24至48个月，以改善L-BMD。
This study investigated whether or not vitamin D and calcium supplementation affected bone metabolism and bone mineral density (BMD) over a period of four years of denosumab therapy in patients with primary osteoporosis. Patients were divided into a denosumab monotherapy group (22 cases) or a denosumab plus vitamin D and calcium supplementation group (combination group, 21 cases). We measured serum bone alkaline phosphatase (BAP), tartrate-resistant acid phosphatase (TRACP)-5b, urinary N-terminal telopeptide of type-I collagen (NTX), and BMD of the lumbar 1–4 vertebrae (L-BMD) and bilateral hips (H-BMD) at baseline and at 12, 24, 36, and 48 months of treatment. There were no significant differences in patient background. Serum BAP, TRACP-5b, and urinary NTX were significantly and comparably inhibited in both groups from 12 to 48 months versus baseline values. L-BMD was significantly increased at every time point in both groups, while H-BMD was significantly increased at every time point in the combination group only. There were significant differences between the groups for L-BMD at 24, 36, and 48 months (P < 0.05) and for H-BMD at 12 months (P < 0.05). Compared with denosumab monotherapy, combination therapy of denosumab plus vitamin D and calcium significantly increased H-BMD at 12 months and L-BMD from 24 to 48 months. These findings indicate that continuous vitamin D and calcium supplementation is important, especially for 12 months to improve H-BMD and from 24 to 48 months to improve L-BMD.
登录
查看更多内容
影响因子：
2.2
作者：
Nakamura, Yukio;Uchiyama, Shigeharu;Kato, Hiroyuki
通讯作者：
Kato, Hiroyuki
在骨质疏松患者中，使用有或没有双膦酸盐预处理的denosumab使用denosumab的血清维生素D和PTH值的变化：一项短期研究。
影响因子：
2.7
作者：
Nakamura Y;Kamimura M;Ikegami S;Mukaiyama K;Uchiyama S;Taguchi A;Kato H
通讯作者：
Kato H
影响因子：
5.8
作者：
Olmos, Jose M.;Hernandez, Jose L.;Gonzalez-Macias, Jesus
通讯作者：
Gonzalez-Macias, Jesus
影响因子：
2
作者：
Suzuki, Takako;Nakamura, Yukio;Kato, Hiroyuki
通讯作者：
Kato, Hiroyuki
影响因子：
2.2
作者：
Uehara, Masashi;Nakamura, Yukio;Kato, Hiroyuki
通讯作者：
Kato, Hiroyuki